Skip to main content
Top
Published in: Medical Oncology 4/2012

01-12-2012 | Original Paper

Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases

Authors: Carsten Nieder, Anca L. Grosu, Kirsten Marienhagen, Nicolaus H. Andratschke, Hans Geinitz

Published in: Medical Oncology | Issue 4/2012

Login to get access

Abstract

In patients with brain metastases from non-small cell lung cancer, the prognostic impact of primary tumour histology, a feature with increasing implications for choice of systemic therapy, is not well defined. Therefore, a multi-institutional analysis was performed: retrospective uni- and multivariate analyses in 209 patients treated with different approaches including surgery and radiosurgery. While squamous cell and large cell carcinoma patients had comparable survival, those with adenocarcinoma survived significantly longer. In multivariate models, adenocarcinoma histology was confirmed as independent prognostic factor, which complements both recursive partitioning analysis (RPA) classes and diagnosis-specific graded prognostic assessment (GPA). When evaluated together with primary tumour control, extracranial metastases, number of brain metastases, age and performance status as individual covariates rather than RPA or GPA score, adenocarcinoma histology again emerged as significant prognostic factor. A significant but small survival advantage for patients with adenocarcinoma was evident already in the time period before drugs such as pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors were available. However, the gap has widened in recently treated patients. Comparable to patients without brain metastases, primary tumour histology should be taken into account when assessing patients’ prognosis and recommending treatment strategy.
Literature
1.
go back to reference Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011;6:1379–91.PubMedCrossRef Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol. 2011;6:1379–91.PubMedCrossRef
2.
go back to reference Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members. Metastatic non-small cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol. 2011;22:1507–19. Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members. Metastatic non-small cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol. 2011;22:1507–19.
3.
go back to reference Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park). 2011;25:597–601. Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park). 2011;25:597–601.
4.
go back to reference Standfield L, Weston AR, Barraclough H, van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology. 2011;16:1210–20.PubMedCrossRef Standfield L, Weston AR, Barraclough H, van Kooten M, Pavlakis N. Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology. 2011;16:1210–20.PubMedCrossRef
5.
go back to reference Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8:381–5.PubMedCrossRef Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011;8:381–5.PubMedCrossRef
6.
go back to reference Tartarone A, Lerose R, Gallucci G, Ardito R, Aieta M. Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non-small cell lung cancer. Med Oncol. 2011. [Epub ahead of print]. Tartarone A, Lerose R, Gallucci G, Ardito R, Aieta M. Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non-small cell lung cancer. Med Oncol. 2011. [Epub ahead of print].
7.
go back to reference Holgersson G, Bergström S, Bergqvist M, et al. Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur J Cancer. 2011;47:2415–21.PubMedCrossRef Holgersson G, Bergström S, Bergqvist M, et al. Swedish lung cancer radiation study group: predictive value of histology for radiotherapy response in patients with non-small cell lung cancer. Eur J Cancer. 2011;47:2415–21.PubMedCrossRef
8.
go back to reference Abacioglu U, Caglar H, Atasoy BM, Abdulloev T, Akgun Z, Kilic T. Gamma knife radiosurgery in non-small cell lung cancer patients with brain metastases: treatment results and prognostic factors. J BUON. 2010;15:274–80.PubMed Abacioglu U, Caglar H, Atasoy BM, Abdulloev T, Akgun Z, Kilic T. Gamma knife radiosurgery in non-small cell lung cancer patients with brain metastases: treatment results and prognostic factors. J BUON. 2010;15:274–80.PubMed
9.
go back to reference Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg. 2002;97:1276–81.PubMedCrossRef Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg. 2002;97:1276–81.PubMedCrossRef
10.
go back to reference Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001;119:1469–75.PubMedCrossRef Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest. 2001;119:1469–75.PubMedCrossRef
11.
go back to reference Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer. 2010;117:2505–12.CrossRef Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H. Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer. 2010;117:2505–12.CrossRef
12.
go back to reference Nieder C, Norum J, Stemland JG, Dalhaug A. Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology. 2010;78:348–55.PubMedCrossRef Nieder C, Norum J, Stemland JG, Dalhaug A. Resource utilization in patients with brain metastases managed with best supportive care, radiotherapy and/or surgical resection: a Markov analysis. Oncology. 2010;78:348–55.PubMedCrossRef
13.
go back to reference Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–51.PubMedCrossRef Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–51.PubMedCrossRef
14.
go back to reference Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655–61.PubMedCrossRef Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655–61.PubMedCrossRef
15.
go back to reference Rades D, Schild SE, Lohynska R, et al. Two radiation regimens and prognostic factors for brain metastases in non-small cell lung cancer patients. Cancer. 2007;110:1077–82.PubMedCrossRef Rades D, Schild SE, Lohynska R, et al. Two radiation regimens and prognostic factors for brain metastases in non-small cell lung cancer patients. Cancer. 2007;110:1077–82.PubMedCrossRef
16.
go back to reference Gülbaş H, Erkal HS, Serin M. The use of recursive partitioning analysis grouping in patients with brain metastases from non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:193–6.PubMedCrossRef Gülbaş H, Erkal HS, Serin M. The use of recursive partitioning analysis grouping in patients with brain metastases from non-small cell lung cancer. Jpn J Clin Oncol. 2006;36:193–6.PubMedCrossRef
17.
go back to reference Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32:129–36.PubMedCrossRef Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32:129–36.PubMedCrossRef
18.
go back to reference Paech DC, Weston AR, Pavlakis N, et al. A systematic review of the interobserver variability for histology in the differentiation between squamous and non-squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:55–63.PubMedCrossRef Paech DC, Weston AR, Pavlakis N, et al. A systematic review of the interobserver variability for histology in the differentiation between squamous and non-squamous non-small cell lung cancer. J Thorac Oncol. 2011;6:55–63.PubMedCrossRef
19.
go back to reference Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–10.PubMed Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J Thorac Oncol. 2006;1:205–10.PubMed
20.
go back to reference Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242:882–8.PubMedCrossRef Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242:882–8.PubMedCrossRef
21.
go back to reference Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRef Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–72.PubMedCrossRef
22.
go back to reference Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity. Int J Radiat Oncol Biol Phys. 1994;29:711–7.PubMedCrossRef Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity. Int J Radiat Oncol Biol Phys. 1994;29:711–7.PubMedCrossRef
23.
go back to reference Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRef Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494–500.PubMedCrossRef
24.
go back to reference Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:33–43.PubMedCrossRef Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:33–43.PubMedCrossRef
25.
go back to reference Linskey ME, Andrews DW, Asher AL et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:45–68. Erratum in: J Neurooncol. 2010;96:69–70. Linskey ME, Andrews DW, Asher AL et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:45–68. Erratum in: J Neurooncol. 2010;96:69–70.
26.
go back to reference Lo SS, Clarke JW, Grecula JC, McGregor JM, Mayr NA, Cavaliere R, Kendra KL, Gupta N, Wang JZ, Sarkar A, Olencki TE. Stereotactic radiosurgery alone for patients with 1–4 radioresistant brain metastases. Med Oncol. 2011;28(Suppl 1):S439–44.PubMedCrossRef Lo SS, Clarke JW, Grecula JC, McGregor JM, Mayr NA, Cavaliere R, Kendra KL, Gupta N, Wang JZ, Sarkar A, Olencki TE. Stereotactic radiosurgery alone for patients with 1–4 radioresistant brain metastases. Med Oncol. 2011;28(Suppl 1):S439–44.PubMedCrossRef
27.
go back to reference Kim JH, Kim HS, Kwon JH, et al. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study. Lung Cancer. 2009;63:405–9.PubMedCrossRef Kim JH, Kim HS, Kwon JH, et al. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study. Lung Cancer. 2009;63:405–9.PubMedCrossRef
28.
go back to reference Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:71–83.PubMedCrossRef Mehta MP, Paleologos NA, Mikkelsen T, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:71–83.PubMedCrossRef
Metadata
Title
Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases
Authors
Carsten Nieder
Anca L. Grosu
Kirsten Marienhagen
Nicolaus H. Andratschke
Hans Geinitz
Publication date
01-12-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-012-0221-0

Other articles of this Issue 4/2012

Medical Oncology 4/2012 Go to the issue